Passive and active immunization targeting PrP is emerging as a potential therapeutic approach for prion disease and current experience suggests that this can be done safely, but with certain caveats that include consideration of epitopes targeted, dosage, and routes of administration (Wisniewski and Goñi, 2018; Ma and Ma, 2020). This evidence concerns the gene PRNP and prion disease.